Hepatitis C treatment market
Hepatitis C is an infectious disease caused by Hepatitis C virus (HCV) and affects primarily the liver. Hepatitis C is commonly caused by blood to blood contacts such as intravenous drug use, unsterilized equipment, blood transfusions, and sexual intercourse. Hepatitis C may also cause from mother to fetus during birth. People with alcoholism and HIV infection of any age group are at increased risk. Currently, there is no vaccine available to treat hepatitis C conditions. However, various drugs such as protease inhibitors, HCV polymerase inhibitors, and HCV NS5A inhibitors are commonly used to treat Hepatitis C. Early stage of infection typically has no symptoms.
The critical stage of infection may display symptoms such as fever, dark urine, abdominal pain, and yellow-tinged skin occurrence. The severity in hepatitis C may lead to liver cirrhosis, liver cancer, liver failure, and sometimes also causes the dilated blood vessels in the oesophagus and stomach. Hepatitis C can be prevented by using sterilized equipment, screening of blood donors, avoiding multiple sexual partners, and avoiding sharing of injections and razors.
Hepatitis C Treatment Market Growth Analysis
The global Hepatitis C treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis C infection. Rising awareness regarding Hepatitis C treatment, increase in healthcare expenditure, and government initiatives and various NGO’s creating awareness regarding the Hepatitis C treatment is expected to fuel the market growth over the forecast period. In addition, rise in the funding in research and development activities for Hepatitis C treatment and strong pipeline products might boost the global market over the forecast period. However, lack of antibiotics in the market, high cost of medications, and lack of hepatitis C infection awareness in poor countries might hamper the growth of the market over the forecast period.
Increase in prevalence of hepatitis C infection and liver cirrhosis expected to fuel the growth of the market. According to the World Health Organization (WHO), globally there are 80 Mn people suffers from chronic hepatitis C virus, in that approximately 700,000 will die each year as a result of the infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their market share in global hepatitis C treatment market.
For instance, in July 2011, Merck MSD, inked an agreement with Roche for the marketing approvals of Victreli (Boceprevir) triple combination therapy with peginterferon alfa and ribavirin (peg/riba). In addition, in August 2011, Vertex Pharmaceuticals Incorporated announced that Health Canada approved its Incivektm (Telaprevir) tablets for people with genotype 1 chronic hepatitis C with compensated liver disease. In January 2014, European Commission (EC) granted marketing authorization for Gilead’s Sovaldi (Sofosbuvir) to treat chronic hepatitis C infection.
Global Hepatitis C treatment market is segmented on the basis of drug class, route of administration, and distribution channel
Based on drug class, the market has been segmented into the following:
- Polymerase Inhibitors
- NS5A Inhibitors
- HCV protease inhibitors
- Combination Therapy
Based on route of administration, the market has been segmented into the following:
Based on distribution channel, the market has been segmented into the following:
- Retail Pharmacies
- Hospital Pharmacies
Geographically, the hepatitis C treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global market followed by Europe and Asia-Pacific. Increase in prevalence of hepatitis C infection (according to Centres for Disease Prevention and Control (CDC), approximately 2.7-3.9 Mn people in the United States are chronically infected with hepatitis C Virus), rise in the awareness among the key stakeholders towards the use of novel products and technologies to treat the hepatitis C, and increase in research and development activities are the key factors bolster the market in North America region.
Europe holds a key share in market owing to increase in prevalence of Hepatitis C infection (according to European centre for Disease Prevention and Control approximately 5.9 Mn people are suffering from HCV infection), rise in the geriatric population, change in the lifestyle, people involving in unprotected sexual intercourse, and increase in the research and development activities might boost the market in Europe region. Asia-Pacific hepatitis C treatment market growth is attributed to increase in the prevalence of hepatitis C infection, rise in the population in Asia-Pacific region, and increase in the healthcare infrastructure. The Middle East & Africa region has high prevalence of HCV infection majorly in Egypt that is approximately 8434 prevalent cases per 100,000 people.
Hepatitis C treatment market leaders are GlaxoSmithKline, plc. (U.K.), Bristol-Myers Squibb (U.S), F. Hoffmann- La Roche Ltd. (Switzerland), Merck & Co, Inc. (U.S), Johnson & Johnson Services, Inc. (U.S.), Gilead Sciences (U.S.), AbbVie Inc. (U.S.), Vertex Pharmaceuticals Inc. (U.S.), and Kadmon Holdings, Inc. (U.S.) to name a few.
- In August 2017, AbbVie received FDA approval for Mavyret (glecaprevir/pibrentasvir), for the chronic hepatitis C virus (HCV) infection in all major genotypes (GT1-6)
- In July 2017, Gilead Sciences, Inc. received U.S. FDA approval for Vosevi used in re-treatment of the chronic hepatitis C virus (HCV) infection
- In May 2015, Bristol-Myers Squibb received U.S. FDA breakthrough therapy designation for investigational drug Daclatasvir-based hepatitis C regimen
- The report provides granular level information about the market size, regional market share and forecast from 2017-2024
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario